IDEAYA receives fast track designation for breast cancer therapy

IDE161 is intended to treat adult patients with advanced or metastatic hormone receptor-positive (HR+), Her2- breast cancer with germline or somatic BRCA 1/2 mutations. Credit: National Cancer Institute on Unsplash.